Ying Huang has spent the past sev­en years build­ing up one of the lead­ing can­cer cell ther­a­py play­ers.

Now, just weeks af­ter an­nounc­ing his de­par­ture...

Epi­crispr Biotech­nolo­gies has raised $90 mil­lion for its Se­ries C round af­ter shar­ing promis­ing ear­ly da­ta around a po­ten­tial new way to treat a rare...

Plus news about Tenax Ther­a­peu­tics, Au­re­ka Biotech­nolo­gies, ATyr Phar­ma, Prana Ther­a­pies and Mereo Bio­Phar­ma.

💸 Lil­ly’s vac­cine ac­qui­si­tions:In May, Eli Lil­ly said it would...

Vaderis Ther­a­peu­tics’ bet that a type of treat­ment de­vel­oped for can­cers could work for a rare blood dis­or­der is pay­ing off.

The 13-per­son Swiss start­up...

The FDA re­ject­ed ITM Iso­tope Tech­nolo­gies Mu­nich’s ra­dio­phar­ma­ceu­ti­cal agent for neu­roen­docrine tu­mors be­cause of man­u­fac­tur­ing is­sues, de­lay­ing a po­ten­tial chal­lenger to No­var­tis’ ap­proved drug Lu­tathera...

Pres­i­dent Don­ald Trump fur­ther as­sert­ed con­trol over the na­tion’s child­hood vac­cine sched­ule, call­ing for the measles, mumps and rubel­la (MMR) vac­cine to split in­to three...